The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV)BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Dat ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination ...

Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...

"Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204." How would you ...

Copyright 2025 The Associated Press. All Rights Reserved. St. Louis County Executive Sam Page speaks during a news conference in Town and Country, Mo., on June 23 ...

Donald and Melania Trump captivated guests at Mar-a-Lago with their energetic performance at the New Year's Eve party (Getty Images) PALM BEACH, FLORIDA: The Trump family ushered in the New Year with ...